1,034 Shares in Cencora, Inc. (NYSE:COR) Purchased by Waverly Advisors LLC

Waverly Advisors LLC acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,034 shares of the company's stock, valued at approximately $232,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in COR. JFS Wealth Advisors LLC grew its holdings in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new position in Cencora in the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. bought a new position in Cencora in the 4th quarter worth approximately $30,000. Kentucky Trust Co bought a new position in Cencora in the 4th quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co grew its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after buying an additional 46 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

COR has been the subject of a number of recent analyst reports. Citigroup increased their price objective on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Robert W. Baird upped their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on Cencora in a research report on Tuesday, April 15th. UBS Group upped their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Finally, Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $301.18.

Cencora Stock Down 1.4%

NYSE:COR traded down $4.06 during trading hours on Wednesday, hitting $289.33. 983,285 shares of the stock traded hands, compared to its average volume of 1,543,396. The firm has a 50 day moving average price of $283.90 and a 200 day moving average price of $257.97. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35. The firm has a market cap of $56.08 billion, a price-to-earnings ratio of 41.16, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the previous year, the business earned $3.80 EPS. The company's revenue was up 10.3% on a year-over-year basis. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date is Friday, May 16th. Cencora's payout ratio is 25.52%.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares of the company's stock, valued at $85,680,732.63. This trade represents a 4.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,223 shares of company stock worth $12,369,767 over the last ninety days. Company insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.